From Yahoo Finance: 2025-05-17 13:36:00

A U.S. district court rules in favor of Acadia Pharmaceuticals in their Nuplazid patent infringement lawsuit with Aurobindo, confirming Aurobindo infringed on claims 4 and 5 of Acadia’s formulation patent. Analysts believe this extends patent protection for pimavanserin from 2030 to 2038, removing a key concern. Outperform rating and $24 price target reiterated on Acadia shares.

Source: TheFly.

For more information on ACAD, visit Disclaimer & Disclosure or Report an Issue.

Read more: Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital